Abstract
α-glucosidase inhibitors (AGIs) have been an important category of oral antidiabetic drugs being widely exploited for the effective management of type 2 diabetes mellitus. However, the marketed AGIs not only inhibited the disaccharidases, but also exhibited an excessive inhibitory effect on α-amylase, resulting in undesirable gastrointestinal side effects. Compared to these agents, Ramulus Mori alkaloids (SZ-A), was a group of effective alkaloids from natural Morus alba L., and showed excellent hypoglycemic effect and fewer side effects in the Phase II/III clinical trials. Thus, this paper aims to investigate the selective inhibitory effect and mechanism of SZ-A and its major active ingredients (1-DNJ, FA and DAB) on different α-glucosidases (α-amylase and disaccharidases) by using a combination of kinetic analysis and molecular docking approaches. From the results, SZ-A displayed a strong inhibitory effect on maltase and sucrase with an IC50 of 0.06 μg/mL and 0.03 μg/mL, respectively, which was similar to the positive control of acarbose with an IC50 of 0.07 μg/mL and 0.68 μg/mL. With regard to α-amylase, SZ-A exhibited no inhibitory activity at 100 μg/mL, while acarbose showed an obvious inhibitory effect with an IC50 of 1.74 μg/mL. The above analysis demonstrated that SZ-A could selectively inhibit disaccharidase to reduce hyperglycemia with a reversible competitive inhibition, which was primarily attributed to the three major active ingredients of SZ-A, especially 1-DNJ molecule. In the light of these findings, molecular docking study was utilized to analyze their inhibition mechanisms at molecular level. It pointed out that acarbose with a four-ring structure could perform desirable interactions with various α-glucosidases, while the three active ingredients of SZ-A, belonging to monocyclic compounds, had a high affinity to the active site of disaccharidases through forming a wide range of hydrogen bonds, whose affinity and consensus score with α-amylase was significantly lower than that of acarbose. Our study illustrates the selective inhibition mechanism of SZ-A on α-glucosidase for the first time, which is of great importance for the treatment of type 2 diabetes mellitus.
Highlights
Molecules2019, 24, x FOR PEER REVIEWNon-insulin-dependent diabetes mellitus has become a serious healthIn our study, we provide a reliable strategy to understand the selective inhibitory effect and concern characterized by hyperglycemia due to inadequate production of insulin, causing complications mechanism of SZ-A on disaccharidases and α-amylase
We provide a reliable strategy to understand the selective inhibitory effect and concern characterized by hyperglycemia due to inadequate production of insulin, causing complications mechanism of SZ-A on disaccharidases and α-amylase
Most of the research is limited to the enzymatic activity assay and determination methods, and few reports are available on the selective inhibition mechanism of 1-DNJ
Summary
We provide a reliable strategy to understand the selective inhibitory effect and concern characterized by hyperglycemia due to inadequate production of insulin, causing complications mechanism of SZ-A on disaccharidases and α-amylase. Oral antidiabetic drugs, α-glucosidase inhibitors (AGIs) are well received among Asian populations, molecular docking was performed to provide valuable insights into the binding properties between which can significantly delay the intestinal carbohydrate digestion and reduce the postprandial blood the major active ingredients (1-DNJ, FA and DAB) and the α-glucosidase [17,18,19]. The excessive inhibition of α-amylase by AGIs will result in gastrointestinal maltase-glucoamylase N-terminal subunit (NtMGAM), maltase-glucoamylase C-terminal subunit side effects because of an increase of undigested carbohydrate and intestinal fermentation.
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have